Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon‐13 and carbon‐14
Journal of Labelled Compounds and Radiopharmaceuticals · 30.05.2015 · 58 (6) · 250-260
DOI: 10.1002/jlcr.3294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, online erschienen am 11.05.2015. Verfasst von Bachir Latli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, 06877-0368, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Deleobuvir, (2 E )‐3‐(2‐{1‐[2‐(5‐bromopyrimidin‐2‐yl)‐3‐cyclopentyl‐1‐methyl‐1 H ‐indole‐6‐carboxamido]cyclobutyl}‐1‐methyl‐1 H ‐benzimidazol‐6‐yl)prop‐2‐enoic acid (1), is a non‐nucleoside, potent, and selective inhibitor of hepatitis C virus NS5B polymerase. Herein, we describe the detailed synthesis of this compound labeled with carbon‐13 and carbon‐14. The synthesis of its three major metabolites, namely, the reduced double bond metabolite (2) and the acyl glucuronide derivatives of (1) and (2), is also reported. Aniline‐ 13 C 6 was the starting material to prepare butyl ( E )‐3‐(3‐methylamino‐4‐nitrophenyl‐ 13 C 6 )acrylate [ 13 C 6 ]‐(11) in six steps. This intermediate was then used to obtain [ 13 C 6 ]‐(1) and [ 13 C 6 ]‐(2) in five and four more steps, respectively. For the radioactive synthesis, potassium cyanide‐ 14 C was used to prepare 1‐cylobutylaminoacid [ 14 C]‐(23) via Buchrer–Bergs reaction. The carbonyl chloride of this acid was then used to access both [ 14 C]‐(1) and [ 14 C]‐(2) in four steps. The acyl glucuronide derivatives [ 13 C 6 ]‐(3), [ 13 C 6 ]‐(4) and [ 14 C]‐(3) were synthesized in three steps from the acids [ 13 C 6 ]‐(1), [ 13 C 6 ]‐(2) and [ 14 C]‐(1) using known procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, 06877-0368, USA.
Zitieren
APA
Latli, B., Hrapchak, M., Chevliakov, M., Li, G., Campbell, S., Busacca, C. A., & Senanayake, C. H. (2015). Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon‐13 and carbon‐14. Journal of Labelled Compounds and Radiopharmaceuticals, 58(6), 250-260. https://doi.org/10.1002/jlcr.3294
Vancouver
Latli B, Hrapchak M, Chevliakov M, Li G, Campbell S, Busacca CA, et al. Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon‐13 and carbon‐14. Journal of Labelled Compounds and Radiopharmaceuticals. 2015;58(6):250-260. doi:10.1002/jlcr.3294
BibTeX
@article{Latli2015,
author = {Latli, Bachir and Hrapchak, Matt and Chevliakov, Maxim and Li, Guisheng and Campbell, Scot and Busacca, Carl A and Senanayake, Chris H},
title = {Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon‐13 and carbon‐14},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2015},
volume = {58},
number = {6},
pages = {250--260},
doi = {10.1002/jlcr.3294}
}
EUVIMED